M&AInnate immunity merger raises €75mForbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics. more ➔
partnershipRoche jumps ship on AC ImmuneGenentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the … more ➔
NGTDeregulation of new genomic techniques before decisionAfter the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic tec … more ➔
bioeconomyAmsilk partners with 21st.BIOAMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins. more ➔
financingOnera Health raises US$32m in Series C round Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv. more ➔
DealSpexis sells antibiotics programme to BasileaMacrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd. more ➔
financingFinnish Enifer Oy secures €12m grant to scale upMicrobial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually. more ➔
financingMogu Srl raises €11m to scale mycelium technologyItalian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC) more ➔
FinancingNovo Nordisk Foundation in US$25m partnership with CARB-XNovo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections. more ➔
M&ANovartis AG to buy immunology specialist Calypso Biotech BVCalypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175. more ➔
